Evidence map›Paper›PMID 32609846›Full record

ArticleBlood advances2020

Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Ashley Cartwright, Simon J Webster, Annika de Jong, Richard J Dirven, Lisa D S Bloomer, Ahlam M Al-Buhairan, Ulrich Budde, Christer Halldén, David Habart, Jenny Goudemand and 4 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. von Willebrand disease and von Willebrand factor.Haemophilia : the official journal of the World Federation of Hemophilia · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Ashley CartwrightHaemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Simon J WebsterHaemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Annika de JongEinthoven Laboratory for Vascular and Regenerative Medicine, Section of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Richard J DirvenEinthoven Laboratory for Vascular and Regenerative Medicine, Section of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Lisa D S BloomerHaemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Ahlam M Al-BuhairanHaemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Ulrich BuddeHämostaseology, Medilys Laborgesellschaft mbH, Hamburg, Germany.
Christer HalldénDepartment of Environmental Science and Biomedicine, Kristianstad University, Kristianstad, Sweden.
David HabartDepartment of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Jenny GoudemandCentre de Référence Maladie de Willebrand, Hématologie, Hôpital Cardiologique, Lille, France; and.
Ian R PeakeHaemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Jeroen C J EikenboomEinthoven Laboratory for Vascular and Regenerative Medicine, Section of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Anne C GoodeveHaemostasis Research Group, Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Daniel J HampshireDepartment of Biomedical Sciences, University of Hull, Hull, United Kingdom.
University of Sheffield · GBLeiden University Medical Center · NLInstitute of Clinical and Experimental Medicine · CZKristianstad University · SELille’s Cardiology Hospital · FRUniversity of Hull · GB

Funding

Zimmerman Program for the Molecular and Clinical Biology of VWDP01HL081588 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2005 to 2016
$19.3M
Zimmerman Program on the Biology of VWDP01HL144457 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2019 to 2023
$13.3M
Molecular Interactions of FVIII and VWFR01HL139847 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2018 to 2021
$2.3M
Medical Research Council MR/K015753/1NHLBI NIH HHS P01 HL081588NHLBI NIH HHS P01 HL144457NHLBI NIH HHS R01 HL139847
6 · The paper itself

Abstract

Copy number variation (CNV) is known to cause all von Willebrand disease (VWD) types, although the associated pathogenic mechanisms involved have not been extensively studied. Notably, in-frame CNV provides a unique opportunity to investigate how specific von Willebrand factor (VWF) domains influence the processing and packaging of the protein. Using multiplex ligation-dependent probe amplification, this study determined the extent to which CNV contributed to VWD in the Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease cohort, highlighting in-frame deletions of exons 3, 4-5, 32-34, and 33-34. Heterozygous in vitro recombinant VWF expression demonstrated that, although deletion of exons 3, 32-34, and 33-34 all resulted in significant reductions in total VWF (P < .0001, P < .001, and P < .01, respectively), only deletion of exons 3 and 32-34 had a significant impact on VWF secretion (P < .0001). High-resolution microscopy of heterozygous and homozygous deletions confirmed these observations, indicating that deletion of exons 3 and 32-34 severely impaired pseudo-Weibel-Palade body (WPB) formation, whereas deletion of exons 33-34 did not, with this variant still exhibiting pseudo-WPB formation similar to wild-type VWF. In-frame deletions in VWD, therefore, contribute to pathogenesis via moderate or severe defects in VWF biosynthesis and secretion.

Indexed as

von Willebrand Diseasesvon Willebrand Disease, Type 1DNA Copy Number VariationsHumansvon Willebrand FactorWeibel-Palade Bodiesvon Willebrand Factor

Identifiers

PMID32609846
PMCPMC7362359
OpenAlexW3038688534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.